Literature DB >> 26198293

Constitutional genetic association with CALR mutations?

L Eder-Azanza1,2, P Evans3, C Wickham4, S Akiki5, J L Vizmanos2, A Chase1,6, N C P Cross1,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26198293     DOI： 10.1038/leu.2015.186

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

2.  Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.

Authors:  Ayalew Tefferi; Emnet A Wassie; Paola Guglielmelli; Naseema Gangat; Alem A Belachew; Terra L Lasho; Christy Finke; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani; Alexandra P Wolanskyj; Margherita Maffioli; Rosario Casalone; Annalisa Pacilli; Alessandro M Vannucchi; Francesco Passamonti
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

3.  Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.

Authors:  Amy V Jones; Daniel Ward; Matthew Lyon; William Leung; Alison Callaway; Andrew Chase; Carolyn L Dent; Helen E White; Hans G Drexler; Jyoti Nangalia; Chris Mattocks; Nicholas C P Cross
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

4.  Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.

Authors:  A Tefferi; T L Lasho; C Finke; A A Belachew; E A Wassie; R P Ketterling; C A Hanson; A Pardanani
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

5.  Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling.

Authors:  L Eder-Azanza; D Navarro; P Aranaz; F J Novo; N C P Cross; J L Vizmanos
Journal:  Leukemia       Date:  2014-06-12       Impact factor: 11.528

6.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

7.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

8.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

9.  Allelic imbalance in CALR somatic mutagenesis.

Authors:  A S Harutyunyan; R Jäger; D Chen; T Berg; E Rumi; B Gisslinger; D Pietra; H Gisslinger; M Cazzola; R Kralovics
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

10.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245
View more
  1 in total

Review 1.  Recent advances in understanding myelofibrosis and essential thrombocythemia.

Authors:  William Vainchenker; Stefan N Constantinescu; Isabelle Plo
Journal:  F1000Res       Date:  2016-04-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.